Europe Cardiometabolic Diseases Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Cardiovascular disease (CVD), Type 2 diabetes, Hypertension, and Obesity), Treatment (ACE Inhibitors, Diuretics, Glucophage, and Others), Dosage (Tablet, and Injection), Route of Administration (Oral, and Intravenous), End Users (Hospital, Clinic, and Homecare Settings), and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)
Market Introduction
The cardiometabolic disease is characterized by a group of abnormalities and symptoms that raise the risk of individuals developing cardiovascular disease. Hypertension, obesity, insulin resistance, dyslipidemia, poor cholesterol profile (LDL), and glucose tolerance are some of the symptoms. Individuals suffering from cardiometabolic syndrome are prone to several other life-threatening diseases such as type 2 diabetes, stroke, coronary artery disease (CAD), cardiovascular disease (CVD), and many others.
Moreover, the increasing prevalence of cardiometabolic diseases is expected to bolster the market growth during the forecast period. However, underdiagnosis of CVDs in low- and middle-income countries (LMICs) limits the growth of the Europe cardiometabolic diseases market.
In Europe, the COVID-19 pandemic has significant implications on the cardiovascular care of patients. Those living with pre-existing cardiovascular diseases have an increased risk of health deterioration and death on contracting COVID-19. Prevention, diagnosis, and treatment services for CVDs have been severely disrupted since the COVID-19 pandemic. According to MedTech Europe, around 95% of all COVID-19 deaths had at least one underlying condition, with cardiovascular disease being the leading comorbidity (65%). Also, around 50% decrease in the number of people visiting at hospitals and other health care facilities with symptoms of heart attacks or stroke, creating a significant backlog of patients with severe health conditions. Also, a reduction in emergency department attendances for cardiac presentation compared with the previous year dropped by between 31% and 88% after a lockdown in the UK, negatively impacting the market growth. The pandemic has significantly impacted the market in the short term; however, the market will grow at a moderate pace in the forecast period.
Get more information on this report : 
Market Overview and Dynamics
The Europe cardiometabolic diseases market is projected to reach US$ 33,963.6 million by 2028 from US$ 26,717.5 million in 2021; it is anticipated to grow at a CAGR of 3.5% from 2021 to 2028. An integrated risk tool (IRT), created by Genomics plc, will be used to estimate each patient's risk of developing a CVD within the next 10 years. The company has claimed that if the IRT is applied to everybody aged between 40 and 60 in the UK, it could identify more than 650,000 people at high risk of CVDs, missed by current screening. Apart from this, recent advances on the Internet of Things (IoT), cloud computing, and artificial intelligence (AI) have significantly improved the conventional healthcare system. In August 2021, South Ural State University (SUSU) scientists have developed a model for more effective diagnosis of CVDs and diabetes, using AI and IoT. Moreover, the integration of AI is further offering lucrative opportunities for the growth of the cardiometabolic disease market and is expected to continue supporting this market over the forecast period. In June 2021, The ACC and GE Healthcare collaborated through the support of and participation in ACC's Applied Health Innovation Consortium (AHIC) to build a roadmap for AI and digital technology in cardiology and develop new strategies for improved health outcomes.
Key Market Segments
In terms of type, the cardiovascular disease segment accounted for the largest share of the Europe cardiometabolic diseases market in 2020. In terms of treatment, the ACE inhibitors segment accounted for the largest share of the Europe cardiometabolic diseases market in 2020. In terms of dosage, the tablet segment accounted for the largest share of the Europe cardiometabolic diseases market in 2020. In terms of route of administration, the oral segment accounted for the largest share of the Europe cardiometabolic diseases market in 2020. In terms of end user, the hospital segment accounted for the largest share of the Europe cardiometabolic diseases market in 2020. Further, based on distribution channel, the hospital pharmacy segment held the largest market share in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the cardiometabolic diseases market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Eli Lilly and Company., Bayer AG, Novartis AG, Boehringer Ingelheim International Gmbh, Novo Nordisk A/S, AstraZeneca, Alnylam Pharmaceuticals, Inc., and Kowa Company, Ltd.
Reasons to Buy Report
- To understand the Europe cardiometabolic diseases market landscape and identify market segments that are likely to guarantee a strong return
- To comprehend the ever-changing market landscape and stay ahead in competition
- To efficiently plan merger and acquisition, and partnership deals in the Europe cardiometabolic diseases market by identifying segments with the most promising probable sales
- To make knowledgeable business decisions from perceptive and comprehensive analysis of the market performance of various segments
- To obtain market revenue forecast of the Europe cardiometabolic diseases market based on various segments for the period 2021–2028
EUROPE CARDIOMETABOLIC DISEASES MARKET SEGMENTATION
- Cardiovascular disease (CVD)
- Type 2 diabetes
- Hypertension
- Obesity
- ACE inhibitors
- Diuretics
- Glucophage
- Others
- Tablet
- Injection
- Oral
- Intravenous
- Hospital
- Clinic
- Homecare settings
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Country
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
Companies Mentioned
- Eli Lilly and Company.
- Bayer AG
- Novartis AG
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
- Alnylam Pharmaceuticals, Inc.
- Kowa Company, Ltd.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.7 Europe Cardiometabolic Diseases market – By Country
2. Europe Cardiometabolic Diseases Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Cardiometabolic Diseases Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Expert Opinions
5. Europe Cardiometabolic Diseases Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Cardiometabolic Diseases
5.1.2 Innovation in Cardiometabolic Diseases Therapeutics
5.2 Market Restraints
5.2.1 Underdiagnosis of CVDs in Low- and Middle-Income Countries (LMICs)
5.3 Market Opportunities
5.3.1 Technological Advancements in CMD Diagnosis
5.4 Future Trends
5.4.1 Personalized Treatment for CMDs
5.5 Impact Analysis
6. Europe Cardiometabolic Diseases Market – Regional Analysis
6.1 Europe Cardiometabolic Diseases Market Revenue Forecast And Analysis
7. Europe Cardiometabolic Diseases Market Analysis – By Type
7.1 Overview
7.2 Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
7.3 Cardiovascular Disease (CVD)
7.3.1 Overview
7.3.2 Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.4 Hypertension
7.4.1 Overview
7.4.2 Hypertension: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.5 Type 2 Diabetes
7.5.1 Overview
7.5.2 Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.6 Obesity
7.6.1 Overview
7.6.2 Obesity: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8. Europe Cardiometabolic Diseases Market Analysis – By Treatment
8.1 Overview
8.2 Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
8.3 ACE inhibitors
8.3.1 Overview
8.3.2 ACE: Cardiometabolic Diseases Inhibitors Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Diuretics
8.4.1 Overview
8.4.2 Diuretics: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.5 Glucophage
8.5.1 Overview
8.5.2 Glucophage: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.6 Others
8.6.1 Overview
8.6.2 Others: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9. Europe Cardiometabolic Diseases Market Analysis – By Dosage
9.1 Overview
9.2 Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
9.3 Tablet
9.3.1 Overview
9.3.2 Tablet: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Injection
9.4.1 Overview
9.4.2 Injection: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
10. Europe Cardiometabolic Diseases Market Analysis – By Route of Administration
10.1 Overview
10.2 Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
10.3 Oral
10.3.1 Overview
10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Mn)
10.4 Intravenous
10.4.1 Overview
10.4.2 Intravenous Market Revenue and Forecast to 2028 (US$ Mn)
11. Europe Cardiometabolic Diseases Market Analysis – By End User
11.1 Overview
11.2 Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
11.3 Clinic
11.3.1 Overview
11.3.2 Clinic Market Revenue and Forecast to 2028 (US$ Mn)
11.4 Hospital
11.4.1 Overview
11.4.2 Hospital Market Revenue and Forecast to 2028 (US$ Mn)
11.5 Homecare Settings
11.5.1 Overview
11.5.2 Homecare Settings Market Revenue and Forecast to 2028 (US$ Mn)
12. Europe Cardiometabolic Diseases Market Analysis – By Distribution Channel
12.1 Overview
12.2 Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
12.3 Hospital Pharmacy
12.3.1 Overview
12.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.4 Retail Pharmacy
12.4.1 Overview
12.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.5 Online Pharmacy
12.5.1 Overview
12.5.2 Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
13. Europe Cardiometabolic Diseases Market – Geographic Analysis
13.1 Europe: Cardiometabolic Diseases Market Revenue and Forecasts to 2028
13.1.1 Overview
13.1.2 Europe: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.3 Europe: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.4 Europe: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.5 Europe: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.6 Europe: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.7 Europe: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.1.8 Europe: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.1.9 Europe Cardiometabolic Diseases Market Revenue and Forecasts to 2028, By Country (%)
13.1.9.1 Germany Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.9.1.1 Germany: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.10 Germany: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.11 Germany: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.12 Germany: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.13 Germany: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.14 Germany: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.1.15 Germany: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.1.15.1 UK Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.15.1.1 UK; Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.16 UK: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.17 UK: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.18 UK: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.19 UK: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.20 UK: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.1.21 UK: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.1.21.1 France Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.21.1.1 France: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.22 France: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.23 France: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.24 France: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.25 France: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.26 France: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.1.27 France: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.1.27.1 Italy Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.27.1.1 Italy: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.28 Italy: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.29 Italy: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.30 Italy: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.31 Italy: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.32 Italy: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.1.33 Italy: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.1.33.1 Spain Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.33.1.1 Spain Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.34 Spain: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.35 Spain: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.36 Spain: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.37 Spain: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.38 Spain: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.1.39 Spain: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.1.39.1 Rest of Europe Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.39.1.1 Rest of Europe: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.40 Rest of Europe: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.41 Rest of Europe: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.42 Rest of Europe: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.43 Rest of Europe: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.44 Rest of Europe: Cardiometabolic Diseases Market, by End User Revenue and Forecast to 2028 (USD Million)
13.1.45 Rest of Europe: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
14. Impact of COVID-19 Pandemic on Europe Cardiometabolic Diseases Market
14.1 Europe: Impact Assessment of COVID-19 Pandemic
15. Europe Cardiometabolic Diseases Market – Industry Landscape
15.1 Overview
15.2 Growth Strategies in the Cardiometabolic Diseases Market (%)
15.3 Organic Developments
15.3.1 Overview
15.4 Inorganic Developments
15.4.1 Overview
16. Company Profiles
16.1 Eli Lilly and Company.
16.1.1 Key Facts
16.1.2 Business Description
16.1.3 Products and Services
16.1.4 Financial Overview
16.1.5 SWOT Analysis
16.1.6 Key Developments
16.2 Bayer AG
16.2.1 Key Facts
16.2.2 Business Description
16.2.3 Products and Services
16.2.4 Financial Overview
16.2.5 SWOT Analysis
16.2.6 Key Developments
16.3 Novartis AG
16.3.1 Key Facts
16.3.2 Business Description
16.3.3 Products and Services
16.3.4 Financial Overview
16.3.5 SWOT Analysis
16.3.6 Key Developments
16.4 Boehringer Ingelheim International GmbH
16.4.1 Key Facts
16.4.2 Business Description
16.4.3 Products and Services
16.4.4 Financial Overview
16.4.5 SWOT Analysis
16.4.6 Key Developments
16.5 Novo Nordisk A/S
16.5.1 Key Facts
16.5.2 Business Description
16.5.3 Products and Services
16.5.4 Financial Overview
16.5.5 SWOT Analysis
16.5.6 Key Developments
16.6 AstraZeneca
16.6.1 Key Facts
16.6.2 Business Description
16.6.3 Products and Services
16.6.4 Financial Overview
16.6.5 SWOT Analysis
16.6.6 Key Developments
16.7 Alnylam Pharmaceuticals, Inc.
16.7.1 Key Facts
16.7.2 Business Description
16.7.3 Products and Services
16.7.4 Financial Overview
16.7.5 SWOT Analysis
16.7.6 Key Developments
16.8 Kowa Company, Ltd.
16.8.1 Key Facts
16.8.2 Business Description
16.8.3 Products and Services
16.8.4 Financial Overview
16.8.5 SWOT Analysis
16.8.6 Key Developments
17. Appendix
17.1 About The Insight Partners
17.2 Glossary of Terms
LIST OF TABLES
Table 1. Europe Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 2. Europe Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 3. Europe Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 4. Europe Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 5. Europe Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 6. Europe Cardiometabolic Diseases Market, by Distribution Channel, – Revenue and Forecast to 2028 (USD Million)
Table 7. Germany Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 8. Germany Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 9. Germany Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 10. Germany Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 11. Germany Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 12. Germany Cardiometabolic Diseases Market, by Distribution Channel, – Revenue and Forecast to 2028 (USD Million)
Table 13. UK Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 14. UK Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 15. UK Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 16. UK Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 17. UK Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 18. UK Cardiometabolic Diseases Market, by Distribution Channel, – Revenue and Forecast to 2028 (USD Million)
Table 19. France Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 20. France Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 21. France Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 22. France Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 23. France Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 24. France Cardiometabolic Diseases Market, by Distribution Channel, – Revenue and Forecast to 2028 (USD Million)
Table 25. Italy Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 26. Italy Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 27. Italy Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 28. Italy Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 29. Italy Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 30. Italy Cardiometabolic Diseases Market, by Distribution Channel, – Revenue and Forecast to 2028 (USD Million)
Table 31. Spain Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 32. Spain Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 33. Spain Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 34. Spain Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 35. Spain Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 36. Spain Cardiometabolic Diseases Market, by Distribution Channel, – Revenue and Forecast to 2028 (USD Million)
Table 37. Rest of Europe Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 38. Rest of Europe Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 39. Rest of Europe Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 40. Rest of Europe Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 41. Rest of Europe Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 42. Rest of Europe Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 43. Organic Developments in the Cardiometabolic Diseases Market
Table 44. Inorganic Developments in the Cardiometabolic Diseases Market
Table 45. Glossary of Terms, Europe Cardiometabolic Diseases Market
LIST OF FIGURES
Figure 1. Europe Cardiometabolic Diseases Market Segmentation
Figure 2. Europe Cardiometabolic Diseases Market Overview
Figure 3. Cardiovascular Disease (CVD) Segment Held Largest Share of Type of Europe Cardiometabolic Diseases Market
Figure 4. Europe Cardiometabolic Diseases Market – Leading Country Markets (US$ Million)
Figure 5. Europe Cardiometabolic Diseases Market, Industry Landscape
Figure 6. Europe PEST Analysis
Figure 7. Europe Cardiometabolic Diseases Market Impact Analysis of Drivers and Restraints
Figure 8. Europe Cardiometabolic Diseases Market – Revenue Forecast And Analysis – 2020- 2028
Figure 9. Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
Figure 10. Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 11. Hypertension: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 12. Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 13. Obesity: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 14. Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
Figure 15. ACE inhibitors: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 16. Diuretics: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 17. Glucophage: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 18. Others: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 19. Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
Figure 20. Tablet: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 21. Injection: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 22. Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
Figure 23. Oral Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 24. Intravenous Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 25. Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
Figure 26. Clinic Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 27. Hospital Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 28. Homecare Settings Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 29. Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
Figure 30. Hospital Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 31. Retail Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 32. Online Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 33. Europe: Cardiometabolic Diseases Market Revenue Overview, by Country, 2021 (US$ MN)
Figure 34. Europe Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 35. Europe Cardiometabolic Diseases Market Revenue and Forecasts to 2028, By Country (%)
Figure 36. Germany: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 37. UK: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 38. France: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 39. Italy: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 40. Spain Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 41. Rest of Europe: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 42. Impact of COVID-19 Pandemic on Europe Cardiometabolic Diseases Market
Figure 43. Growth Strategies in the Cardiometabolic Diseases Market (%)
- Eli Lilly and Company.
- Bayer AG
- Novartis AG
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
- Alnylam Pharmaceuticals, Inc.
- Kowa Company, Ltd
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe cardiometabolic diseases market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe cardiometabolic diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.